Business - Briefly   

U.S. FDA nod for Ranbaxy

NEW DELHI, MARCH 15. Ranbaxy Laboratories Ltd (RLL) today said it has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Quinapril Hydrochloride tablets, indicated for the treatment of hypertension. The city-based drugmaker said the drug was a generic form of Pfizer Inc's anti-hypertension drug, Accupril, which had sales worth $589 million in 2003 in the U.S.

Quinapril Hydrochloride is also indicated in the management of heart failure as adjunctive therapy when added to conventional therapy including diuretics and digitalis.

UNI

Printer friendly page  
Send this article to Friends by E-Mail

Business

News: Front Page | National | Tamil Nadu | Andhra Pradesh | Karnataka | Kerala | New Delhi | Other States | International | Opinion | Business | Sport | Miscellaneous |
Advts: Classifieds | Employment | Updates: Breaking News |

Stories in this Section

• Centre mops up Rs. 15,400 cr. from six issues
• FDI proposals worth Rs 530 cr. approved
• Sensex tumbles 180 points in late sell-off
• GM India to roll out `New Age' Chevrolet MUV
• Rupee ends higher against $
• Auto, steel makers agree on five-point agenda
• Entertainment industry poised for growth
• Walt Disney explores India as production base
• LIC MF to launch two equity funds
• West Bengal expects to exceed revenue target
• Stock Market Index
• Bullion rates
• Exchange rates
• 1:1 bonus from Marico
• U.S. FDA nod for Ranbaxy
• Alcatel, ITI join hands
• BPL Mobile's gesture
• Ram Informatics pact with KAFA consortium
• Bank of Baroda ties up with Punjab Tractors
• Zydus Cadila to launch Nucoxia
• Steel Traders Association plea
• Green Thumb Garden's plans
• Cholomandalam to expand presence in M.P.
• EPCH plans global marketing project
• Mercator bags BG Exploration contract

Copyright © 2004, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu